Double Trouble: Bintai Kinden’s partner Generex files trademark and patent for COVID-19 vaccine

Double Trouble: Bintai Kinden’s partner Generex files trademark and patent for COVID-19 vaccine

Latest news reports suggests Bintai Kinden Corporation Bhd’s partner Generex Biotechnology Corporation has filed for a trademark for its il-Key vaccine, also dubbed as ‘The Complete Vaccine’, and a patent for its il-Key-SARS-CoV-2 vaccine.

Bintai Kinden released a statement on 14th January with claims that the il-Key vaccine provides the ‘safest and best route for the rapid development of a COVID-19 vaccine’ which will see children and pregnant women fit for the vaccine, without causing side effects.

The company further states that the il-Key vaccine is configured to ‘regulate the immune system to provide a targeted, neutralising antibody response without generating off-target, non-neutralising antibodies that can lead to antibody dependent enhancement of disease.’

Based on announcement by Generex, Bintai Kinden managing director Ong Choon Lui offers an insight into the development of Generex’s COVID-19 vaccine, stating that it was based on results of the ex-vivo human studies. Generex has begun good manufacturing practice production of several COVID-19 epitopes that will be formulated for the Phase 1 and Phase 2 clinical trials.

Ong states: ‘New drug application is being prepared for the United States’ Food and Drug Administration submission in early 2021. With multiple epitotes that are targeted to generate specific, neturalising regions of the coronavirus without off-target effects, and which have demonstrated positive T-cell regulation necessary for long-term immune memory, the COVID-19 vaccine has the potential to be a complete vaccine.’

A subsidary of Bintai Kinden, Bintai Healthcare Sdn Bhd has been granted the exclusive rights by Generex and its subsidary, NuGenerex Immuno-Oncology Inc to distribute, sell and commercialise the il-Key vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam.

Bintai Healthcare Sdn Bhd has also been given the first right of refusal to distribute and market the vaccine countries including Australia, New Zealand and the global halal market.

This article was written to report and inform based on sources as directed below:

  • The Star, January 2021 (source)
  • The Edge Markets, January 2021 (source)
  • The Malaysian Reserve, January 2021 (source)
Language »